NEW YORK--(BUSINESS WIRE)--OrbiMed is pleased to announce that, as part of ongoing succession planning, Samuel D. Isaly has transferred his controlling interest in OrbiMed and, as a result, is stepping down from his position as Managing Member of the firm. The terms of the transfer were not disclosed.
The firm’s five other Partners, Sven H. Borho, Carl L. Gordon, Jonathan T. Silverstein, W. Carter Neild and Geoffrey C. Hsu, will continue their ownership of the firm. Effective immediately, the Managing Member role has been transferred to Mr. Borho, Mr. Gordon and Mr. Silverstein.
Mr. Isaly intends to continue to practice his investment skills as the Chief Investment Officer of the Isaly Family Office, and in other future activities, subject to his obligations to OrbiMed. Mr. Isaly thanks all of his colleagues and friends for their continued support and looks forward to many more years of investing excellence.
About OrbiMed
OrbiMed is a leading healthcare investment firm, with over $14 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, utilizing a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed maintains offices in New York City, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and global team resources and support to help build world-class healthcare companies.
